<DOC>
	<DOCNO>NCT02892123</DOCNO>
	<brief_summary>To evaluate maximal tolerate dose ( MTD ) , optimal biological dose ( OBD ) recommend dose ( RD ) , overall safety tolerability ZW25 , humanize bispecific monoclonal antibody target extracellular domain HER2 , patient locally advance ( unresectable ) and/or metastatic HER2-expressing cancer .</brief_summary>
	<brief_title>Trial ZW25 Patients With Advanced HER2-expressing Cancers</brief_title>
	<detailed_description>This study 2 part . In first part study , patient HER2-expressing cancer either HER2 1+ , 2+ 3+ immunohistochemistry ( IHC ) progress standard care therapy receive escalate dos ZW25 order identify either high dose study drug possible cause unacceptable side effect dose study drug think associate optimal biologic activity . In second part study , patient enrol one cohort base level HER2 expression cancer type . - Cohort 1 : HER2 IHC 2+/FISH negative breast cancer - Cohort 2 : HER2 IHC 3+ HER2 IHC 2+/FISH positive breast cancer - Cohort 3 : HER2 IHC 2+/FISH negative gastric/ GEJ cancer - Cohort 4 : HER2 IHC 3+ HER2 IHC 2+/FISH positive gastric/GEJ cancer - Cohort 5 : Any HER2 IHC 2+ 3+ FISH positive cancer Patients receive dose study drug identify Part 1 study . These patient follow evaluate safety ZW25 well explore anti-tumor activity .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . HER2expressing cancer follow : Part 1 : Any locally advanced ( unresectable ) and/or metastatic HER2expressing ( HER2 1+ , 2+ , 3+ IHC ) cancer progress receipt therapy know confer clinical benefit HER2overexpressing ( 3+ IHC ) HER2 2+ FISH positive breast cancer must progress prior treatment trastuzumab , pertuzumab , T‑DM1 HER2overexpressing ( 3+ IHC ) HER2 2+ FISH positive gastric cancer must progress prior treatment trastuzumab Part 2 : − Locally advance ( unresectable ) and/or metastatic cancer progress receipt therapy know confer clinical benefit ( unless ineligible receive specific therapy ) follow : Cohort 1 : HER2 IHC 2+/FISH negative breast cancer Cohort 2 : HER2 IHC 3+ HER2 IHC 2+/FISH positive breast cancer Cohort 3 : HER2 IHC 2+/FISH negative gastric/GEJ cancer Cohort 4 : HER2 IHC 3+ HER2 IHC 2+/FISH positive gastric/GEJ cancer Cohort 5 : Any HER2 IHC 2+ 3+ FISH positive cancer Patients colorectal cancer must KRAS wildtype determine PCR Patients NSCLC must ALK wildtype , EGFR wildtype , ROS1 fusion negative determine standard method . 2 . Male female , ≥ 18 year age time sign informed consent . 3 . ECOG performance status 0 1 4 . Adequate hepatic function , follow : Aspartate aminotransferase ( AST ) ≤2.5 x upper limit normal ( ULN ) per institutional value ( liver bone metastasis present , ≤5 x ULN ) Alanine aminotransferase ( ALT ) ≤2.5 x ULN per institutional value ( liver bone metastasis present , ≤5 x ULN ) Total bilirubin ≤1.5 x ULN per institutional value 5 . Adequate renal function ( within normal limit per institution calculate glomerular filtration rate &gt; 50 ) 6 . Hematological function , follow : Absolute neutrophil count ( ANC ) ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin ≥9g/dL Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.5 x ULN 7 . Adequate cardiac leave ventricular function , define leave ventricular ejection fraction ( LVEF ) institutional standard normal 8 . For Part 1 : evaluable disease ( target nontarget lesion per RECIST version 1.1 ) . For Part 2 : measurable disease ( target lesion per RECIST version 1.1 ) 9 . Able provide fresh formalinfixed , paraffinembedded ( FFPE ) tumor sample central evaluation HER2 status prior enrolment ; fresh biopsy feasible , sponsor approval require archived tumor biopsy must provide centralized testing sponsor For Part 1 , eligibility may base local read ( use ASCO/CAP guideline ) fresh archive tumor biopsy . However , archive fresh FFPE biopsy must provide retrospective centralize review unless otherwise approve 10 . For female patient surgically sterile postmenopausal male patient partner child bearing potential , willingness use 2 method birth control failure rate le 1 % per year study 12 month last dose ZW25 . These include , limited , establish use oral , implanted , injected hormonal contraceptive ; placement intrauterine device intrauterine system ; use barrier method condom diaphragm together spermicide product 1 . Treatment experimental therapy within 4 week first ZW25 dose 2 . Treatment cancer therapy include chemotherapy , small molecule , antibody within 5 halflives cancer therapy first ZW25 dose 3 . Treatment anthracyclines within 90 day first ZW25 dose lifetime load exceed 300 mg/m2 first ZW25 dose adriamycin equivalent first ZW25 dose 4 . Treatment trastuzumab , pertuzumab , lapatinib , T‑DM1 within 3 week first ZW25 dose 5 . Untreated brain metastasis ( patient treat brain metastasis steroids anticonvulsant stable least 1 month time Screening eligible ) 6 . Pregnant breastfeed woman 7 . History lifethreatening hypersensitivity monoclonal antibody recombinant proteins excipients drug formulation 8 . Acute chronic uncontrolled renal disease , pancreatitis liver disease ( exception patient Gilbert 's Syndrome , asymptomatic gall stone , liver metastasis , stable chronic liver disease per investigator assessment ) 9 . Peripheral neuropathy ≥Grade 2 NCICTCAE version 4.03 , 14 July 2010 10 . Clinically significant interstitial lung disease 11 . Known active hepatitis B C know infection human immunodeficiency virus 12 . Use immunosuppressive steroid within 3 month first ZW25 dosing , except chronic steroid dose ≤15 mg per day prednisone equivalent dose adrenal insufficiency 13 . QTc Fridericia ( QTcF ) &gt; 450 m 14 . Having clinically significant cardiac disease ventricular arrhythmia require therapy , uncontrolled hypertension ( defined persistent systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 100 mm Hg antihypertensive medication ) , history symptomatic CHF 15 . Having know myocardial infarction unstable angina within 6 month first ZW25 dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HER2</keyword>
	<keyword>bispecific antibody</keyword>
	<keyword>biparatopic antibody</keyword>
	<keyword>breast cancer</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>gastroesophageal cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
</DOC>